ArticleClinical cancer research : an official journal of the American Association for Cancer Research2013
Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03233152 (A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma), which is not on this map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma
Who cites it
36 citing papers in PubMed, 53 citations in OpenAlex.
- Trial
- Bronchoscopic Ablation and Intratumoral Therapies for Lung Cancer: Expanding Local Treatment Beyond Surgical Resection.Cancers · 2026Review
- Impact of tumor localization on antitumor immunity with conditionally activated CTLA-4 blockade.Journal for immunotherapy of cancer · 2025Article
- Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma.Neuro-oncology · 2024Article
- Alternative Routes of Administration for Therapeutic Antibodies-State of the Art.Antibodies (Basel, Switzerland) · 2022Review
- Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Intratumoral immunotherapy relies on B and T cell collaboration.Science immunology · 2022Article
- The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021.Journal of translational medicine · 2022Article
- Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8Journal for immunotherapy of cancer · 2022Article
- The antitumor effect induced by an IL-2 'no-alpha' mutein depends on changes in the CD8Frontiers in immunology · 2022Article
- Tumor eradicated by combination of imiquimod and OX40 agonist for in situ vaccination.Cancer science · 2021Article
- Intratumoural administration and tumour tissue targeting of cancer immunotherapies.Nature reviews. Clinical oncology · 2021Review
- Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial.Journal for immunotherapy of cancer · 2021Article
- Toll-Like Receptor-Based Strategies for Cancer Immunotherapy.Journal of immunology research · 2021Review
- Intratumoral Combinatorial Administration of CD1c (BDCA-1)Vaccines · 2020Article
- Immunomodulatory Effects of Radiotherapy.International journal of molecular sciences · 2020Review
- Advances in engineering local drug delivery systems for cancer immunotherapy.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
- Bronchoscopic intratumoural therapies for non-small cell lung cancer.European respiratory review : an official journal of the European Respiratory Society · 2020Review
- Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA4 immune checkpoint antibodies.Journal for immunotherapy of cancer · 2020Article
- Modeling multi-needle injection into solid tumor.American journal of cancer research · 2019Article
Corrections and comments
- Comment on
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Systemic administration of the checkpoint blockade antibody anti-CTLA4 results in severe autoimmune toxicity, limiting its clinical efficacy. Fransen and colleagues show here that peritumoral delivery of low doses of this immunomodulatory drug can trigger a systemic antitumor immune response while preventing the toxicity against other organs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.